

Jenna Rossoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7406541/publications.pdf>

Version: 2024-02-01

23
papers

589
citations

759055

12
h-index

713332

21
g-index

24
all docs

24
docs citations

24
times ranked

770
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 2022, 6, 1961-1968.	2.5	47
2	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 2022, 6, 600-610.	2.5	32
3	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 2022, 40, 945-955.	0.8	79
4	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 2022, 6, 4251-4255.	2.5	20
5	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. Journal of Clinical Oncology, 2022, 40, 10016-10016.	0.8	0
6	Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. Journal of Medical Internet Research, 2021, 23, e24893.	2.1	18
7	Reduced toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatric Blood and Cancer, 2021, 68, e29087.	0.8	4
8	Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL6/JAK inhibition: A pediatric case series. Pediatric Blood and Cancer, 2021, 68, e29261.	0.8	9
9	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood, 2021, 138, 2138-2142.	0.6	5
10	Appendectomy Versus Observation for Appendicitis in Neutropenic Children With Cancer. Pediatrics, 2021, 147, e2020027797.	1.0	10
11	Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients. Pediatric Blood and Cancer, 2020, 67, e28504.	0.8	22
12	Applying the COMB model to patient-reported barriers to medication adherence in pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28216.	0.8	14
13	Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368.	1.2	21
14	Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). Blood, 2020, 136, 14-15.	0.6	25
15	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. Blood, 2020, 136, 42-44.	0.6	8
16	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112.	2.3	102
17	Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 3097-3098.	0.6	1
18	Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience. Open Forum Infectious Diseases, 2019, 6, .	0.4	84

#	ARTICLE	IF	CITATIONS
19	Cell-free DNA next-generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27734.	0.8	73
20	Cost analysis of bronchoalveolar lavage and respiratory tract biopsies in the diagnosis and management of suspected invasive fungal infection in children with cancer or who have undergone stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27598.	0.8	9
21	High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 316-321.	0.3	3
22	Spontaneous remission in congenital leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2271-2272.	0.6	3
23	Initial Management of Fever and Neutropenia: A Practical Approach. <i>Clinical Pediatric Emergency Medicine</i> , 2018, 19, 145-152.	0.4	0